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Periodontal tissue engineering: current strategies
and the role of platelet rich hemoderivatives
Pedro S. Babo, ab Rui L. Reis ab and Manuela E. Gomes *ab
The periodontium is the assembly of tissues that anchor the teeth to the bone and acts like a dumper for
the forces originated during the mastication. The integrity and function of periodontal tissue can be
compromised by periodontitis. This highly prevalent inflammatory disease is clinically treatable, nevertheless
the healing outcomes are not consistent with a functional periodontal tissue. Given the complexity of the
tissues involved and the healing process of the periodontal wound, the development of therapies leading to
consistent and predictable regeneration of functional periodontal tissues, turns out to be a challenge.
Tissue engineering may oﬀer the adequate prospects to address such challenge, which are summarized
in this manuscript. Periodontal tissue engineering procures to regenerate the periodontal wound by
stimulating the self-healing ability of periodontium. Thus, it should include the right combination of
adequate cell types, biochemical stimuli and the provision of a stable matrix to drive the regrowth of
both soft and hard periodontal tissue while avoiding the collapse of soft gingival tissue into periodontal
wound. The use of hierarchically designed compartmentalized systems has been proposed as a viable
strategy for the regeneration of the complex structure of periodontium. Platelet rich hemoderivatives
(PRHds) have been explored for periodontal tissue engineering as sources of cytokines and structural
proteins involved in the modulation of the wound healing. Here will be described the benefits,
limitations and solutions for the application of the PRHds in peridontal tissue engineering.
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Periodontal tissue and periodontal
disease
The periodontal tissue or periodontium is, as the Greek
etymology suggests, the tissue that lies around (peri-) the tooth
(-odons). It is a complex structure that anchors the tooth to the
maxillary or mandibular bone, while withstanding the forces
generated by the masticatory process. The periodontium func-
tion is assured by the assembly of specialized tissues with
specific morphology and functions, that include the cementum
underlying the tooth root surface (Fig. 1D), the periodontal
ligament (Fig. 1E), the alveolar bone (Fig. 1C) and a portion of
the gingiva facing the tooth (dento-gingival junction (Fig. 1*)).1
The breakdown of periodontal tissue can occur as a conse-
quence of trauma or periodontitis, compromising its function.
Periodontal diseases are highly prevalent, aﬀecting up to
90% of human population.2 The accumulation of microbial
plaque in the gingival crevice originates an imbalance in host/
commensal microorganisms’ homeostasis, named dysbiosis,
inducing an inflammatory response in the gingiva (Fig. 2). This
mild-inflammation in gingiva, the gingivitis, does not compro-
mise the underlying tissue. Nevertheless, the chronic gingivitis
may induce an immune-inflammatory response in the host,
characterized by the formation of a periodontal pocket with
resorption of alveolar bone by the action of osteoclasts and
general destruction of periodontal supporting tissue termed
periodontitis (Fig. 2).3 Periodontitis has a multifactorial etiology
involving microbial, behavioral (inadequate oral hygiene, alcohol
and tobacco use), systemic (immune or metabolic diseases), and
genetic factors.4
Loss of connective tissue and bone support as result of
periodontitis is the major cause of tooth loss in adults.3 Besides
the aesthetic and functional compromise as result of teeth loss,
chronic periodontitis has also a risk of systemic complications,
associated with diseases resulting from atherosclerosis, lung
diseases, and adverse pregnancy outcomes.3,5 In US periodontitis
is considered a public health issue, aﬀecting 46% of US adults
representing 64.7 million people, with 8.9% suﬀering from severe
forms of the disease.6
Conventional periodontal treatment
The traditional clinical treatments are based on the halting of
disease progression by means of wound site debridement,
associated with establishment of excellent oral hygiene.7
Nevertheless, the resulting healing patterns are usually not
concomitant with the fully functional regeneration of the
periodontium (Table 1).7,8 The space left void by the destroyed
periodontal tissues is usually populated by epithelial cells that
migrate 10 times faster than the normal periodontal cell types.
Generally, in a periodontal wound, the fast growing of epithe-
lial and gingival tissues usually repopulate the empty space of
the periodontal wound. This invasion blocks the repopulation
of wound by the cementoblasts, PDL cells, and osteoblasts
that could regenerate normal periodontium. Instead, long junc-
tional epithelium is formed. Although the formation of a new
epithelial attachment may be compatible with an acceptable
clinical outcome and clinical health, it does not regenerate the
primitive PDL function.9
The use of occlusive membranes was introduced into
clinical dental practice in the mid-1980’s in order to avoid the
population of periodontal wound with gingival cells. This therapy,
named guided tissue regeneration (GTR) aimed at promoting
the intrinsic healing potential of the alveolar10 and periodontal
ligament origin cells,11,12 that was recently discovered at that
time. It was hypothesized them that if cells derived from the
PDL and alveolar bone were the first to repopulate tooth root
Fig. 1 Normal tooth and periodontal tissue morphology. (A) The crown of
tooth or enamel; (B) dentin; periodontal tissue: (C) alveolar bone, (D)
cementum, (E) periodontal ligament (periodontal fibers: #a alveolar crest,
#b horizontal, #c obliqual fibers), * cementoenamel junction.
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surface, instead of the fast growing gingival epithelial and
connective cells, the formation of a long junctional epithelium
would be avoided, and the regeneration of a functional period-
ontium could be possible.13
Nevertheless, the solely creation of an occlusive barrier is
unlike to promote full periodontal regeneration, i.e. the restau-
ration of form and function of lost periodontal tissue. This fact
justifies an increasing interest in studying tissue engineering
approaches that can trigger periodontal regeneration.
Periodontal tissue engineering
Tissue engineering (TE) emerged as a science that combines
the application of principles of engineering and life sciences on
behalf of the development of techniques that aim at promoting
the regeneration of damaged tissues.7 TE approaches aiming
at periodontal tissue regeneration have been focusing on the
enhancement of the endogenous regenerative potential of the
preserved periodontal tissue10–12 using materials with a well-
defined architecture and providing adequate biochemical stimu-
lus. Pre-requisites for the development of reliable periodontal
regenerative therapies are (1) to provide adequate biological cues
stimulating the first intentional repair from the preserved tissue;
(2) to provide form stability for new tissue ingrowth avoiding the
collapse of soft gingival tissue; and (3) to occlude the area from
the fast-proliferating gingival fibroblasts.8,14
Compartmentalized approaches
As above described, the periodontal tissue has a complex
structure, comprising both soft and hard tissues. Based on
the assumption that the regeneration of functional tissues
depends on the combination of adequate cells with a scaﬀold
presenting well-defined architectures and biochemical signals,
recent TE approaches have proposed compartmentalized systems
for the functional and predictable regeneration of periodontium
(Fig. 3).15–17 Such systems focus on meeting the different
characteristics and requirements of the various tissues involved
in periodontal defects, mainly targeting the alveolar bone and
the periodontal ligament tissues.
Requicha and co-workers18,19 created bi-layered membranes
based on a blend of starch and polycaprolactone (SPCL)
composed by a flat SPCL layer and a SPCL fiber-mesh function-
alized with Si groups. The influence of topography and the
presence of Si groups stimulated the osteogenic diﬀerentiation
Fig. 2 Periodontal diseases: gingivitis versus periodontitis.
Table 1 Diﬀerent patterns of periodontal healing/regeneration (based on Chen et al., 2010,7 and Polimeni et al., 2006;8 adapted from Babo, et al.9)
Pattern Characterization
Long junctional epithelium
(epithelial attachment)
Thin epithelial attachment extended apically along the instrumented root surface, which is formed by
keratinocytes that migrate into the pocket from the crevicular epithelium
Connective tissue repair Healing of periodontal defect by collagen fibers oriented parallel or perpendicularly to a instrumented root
surface previously exposed to periodontal disease or otherwise deprived of its periodontal attachment
Bone and/or bone-like tissue
repair (ankylosis)
Healing of periodontal defect by bone or bone-like tissue formation without specific PDL and/or acellular
extrinsic fiber cementum regeneration
Periodontal tissue regeneration Healing of the periodontal defect by regeneration of tooth cementum, a functionally oriented PDL,
alveolar bone, and gingiva in periodontal defect
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of canine adipose derived stem cells (cASCs) in vitro.18 The
double-layered membrane was also assessed in a mandibular rat
defect model and compared to a commercial collagen membrane
(Parasorb Resodont, Resorba, Germany).19 The SPCL-Si scaﬀolds
induced significantly higher new bone formation in 8 weeks
showing better results than the positive control.19 Iwata and
co-workers20 proposed a multi-layered system in which canine
PDLCs cell sheets, supported by a woven polyglycolic acid matrix,
were transplanted to dental root surfaces and porous b-tricalcium
phosphate (b-TCP) was used to fill the bone defect area. They were
able to regenerate both new bone and cementum connecting with
well-oriented collagen fibers in a canine 3-wall periodontal defect.20
Costa, et al.21 tested a bi-layered system composed by cell sheets of
periodontal ligament cells (PDLCs) targeting the regeneration of
PDL combined with a PCL mesh coated with b-TCP for the
regeneration of alveolar bone. The in vivo ectopic implantation of
this compartmentalized bi-layered system was able to promote the
regeneration PDL-like tissue in the PDLCs cell sheet compartment
and the deposition of new bone in the PCL mesh.21
The combination of state-of-art imaging and tri-dimensional
printing technologies has allowed the printing of tailor-made
compartmentalized constructs emulating the specific shape of
the target periodontal defect.22–24 The three-dimensional bio-
printing allows for reproduction of specific features mimicking
the microarchitecture of the PDL and alveolar bone, or the situ-
specific delivery of cells and biochemical cues.
Delivery of adequate cell types
The cells isolated from the periodontal ligament (PDLCs) have
been widely explored for periodontal TE. Among the PDLCs, are
found stem cells (PDLSCs) that express the mesenchymal stem-cell
markers STRO-1 and CD146/MUC18,25 that are able to diﬀerentiate
into several cell lineages, namely chondrogenic,26 osteogenic,27
cementoblastogenic, adipogenic, and collagen-forming cells.25
Moreover, PDLSCs have the capacity to generate a cementum/
PDL-like structure ectopically,25 as well as to contribute for period-
ontal tissue repair in animal models.20,25,28 However, given the
limited amount on PDL stem cells available in a patient suﬀering
of periodontal tissues loss, other oral and non-oral sources have
been also been considered, namely bone marrow mesenchymal
stem cells (MSCs),29 embryonic stem cells (ESCs),30 adipose tissue
derived stem cells (ASCs)18,31,32 gingival fibroblasts33 or genetically
engineered cells34 (revised in detail in ref. 35).
Growth factors
In addition to an adequate matrix, the TE approaches should be
able to orchestrate temporally and spatially the complex
sequence of events that are involved in the natural formation
Fig. 3 Principles of compartmentalized bi-layered systems. (A) Schematic of a compartmentalized system for periodontal tissue engineering and main
principles addressed by these systems; (B) compartmentalized bi-layered system proposed by Babo et al. 2016,17 composed by a platelet lysate
membrane aiming PDL regeneration and an injectable calcium phosphate (CaP) cement for alveolar bone regeneration tested in a periodontal defect in
rats. Representative histologic micrographs showing the connective tissue reattachment and alveolar bone regrowth.
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and development of periodontium.8 The growth factors (GFs)
that have been found more relevant for periodontal regenera-
tion are PDGF, IGFs, FGF, TGF-b, and BMPs.7 The use of growth
factors with osteogenic potential, namely transforming growth
factor-beta (TGF-b) and bone morphogenic proteins (BMPs)
have been tested for the regeneration of alveolar bone, while
no significant eﬀect in new connective tissue attachment was
achieved.36 Fibroblast growth factor (FGF) which is mitogenic
for PDLFs and induces osteogenic phenotype in vitro,37 was
shown to enhance both alveolar bone and PDL regeneration
in a rat 3-wall defect.36 The combination of diﬀerent growth
factors is expected to have a synergistic eﬀect on the regulation
of periodontal regeneration.
Platelet-rich hemoderivatives
Polimeni et al.,8 revising the periodontal healing and regenera-
tion mechanisms, refers the importance of the stabilization
of blood clot on root surface to avoid epithelial downgrowth,
and promote periodontal tissue regrowth. Platelet-rich hemo-
derivatives (PRHds) have been explored for TE applications as a
simple and cost eﬀective source of GFs, cytokines and struc-
tural proteins with key roles in the regeneration of bone and
soft tissues.38–40 The Table 2 summarizes the principal GFs
found in PRHds with interest for periodontal TE. Among the
growth factors abundant in the PRHds are the transforming
growth factor-b (TGF-b), insulin growth factor-1 (IGF-1),
endothelial growth factor (EGF), platelet derived growth factor
(PDGF), vascular endothelial growth factor (VEGF) and fibroblast
growth factor (FGF).41–43 These soluble factors are involved in
essential stages of wound healing and regenerative processes such
as chemotaxis, cell proliferation and differentiation.43–45 Moreover,
the PRHds are rich in structural proteins, such as fibrinogen46
(or its polymerized product fibrin), and fibronectin,47 which may
act as a provisional matrix for cell adhesion and migration.40
Some PRHds have also been reported to exhibit antimicrobial
properties,48–50 attributed to the presence of b-lysin,51 neutrophil
activating protein-2,52,53 or platelet factor-4,54,55 which can con-
tribute for maintaining the prophylaxis of the wound site.
For TE, the PRHds can be used directly or in combination of
adequate biomaterials (Table 3), depending on the treatment
goal and targeted tissue: delivery of growth factors; cell trans-
plantation; enhance tissue-integration of grafts; improve the
mechanical properties of the system.
The PRHds include several diﬀerent products, which can be
roughly classified into platelet rich plasma (PRP), platelet rich
fibrin (PRF) or platelet lysate (PL). They can be obtained by several
methods, usually after the centrifugation of whole blood, in
order to produce a platelet concentration over the physiologic
Table 2 Growth factors isolated from platelet rich hemoderivatives and its potential role for the regeneration of periodontal tissue
Growth
factor Recommended name Physiologic functions
Potential role in
periodontal regeneration Ref.
BMP-2 Bone morphogenetic protein 2 Induces cartilage and bone formation Alveolar bone regeneration 114
BMP-4 Bone morphogenetic protein 4 Induces cartilage and bone formation Alveolar bone regeneration 114
BMP-6 Bone morphogenetic protein 6 Induces cartilage and bone formation Alveolar bone regeneration 114
PDGF AA Platelet-derived growth
factor AA
Plays an important role in wound
healing. Promotes cellular proliferation,
migration, survival and chemotaxis
Recruitment of progenitor cells
from preserved periodontal
tissue; cell proliferation
104 and
114–117
PDGF AB Platelet-derived growth
factor AB
Plays an important role in wound
healing. Promotes cellular proliferation,
migration, survival and chemotaxis
Recruitment of progenitor cells
from preserved periodontal
tissue; cell proliferation
76, 103 and 114
PDGF BB Platelet-derived growth
factor BB
Plays an important role in wound
healing. Promotes cellular proliferation,
migration, survival and chemotaxis
Recruitment of progenitor cells
from preserved periodontal
tissue; cell proliferation
41, 46, 103, 115
and 118
TGF-b1 Transforming growth
factor beta-1
Plays an important role in bone
remodeling; stimulator of osteoblastic
bone formation, causing chemotaxis,
proliferation and diﬀerentiation in
osteoblast precursor cells
Recruitment and diﬀerentiation
of pre-osteoblasts for the
regeneration of alveolar bone
41, 42, 46, 76,
103, 115 and
117
TGF-b2 Transforming growth
factor beta-2
Stimulates the proliferation of osteoblast
precursor cells, and bone collagen
synthesis. TGF-b2 has suppressive eﬀects
on interleukin-2 dependent T-cell growth
Recruitment of and diﬀerentia-
tion of pre-osteoblasts for the
regeneration of alveolar bone
103, 115 and
116
IGF-I Insulin-like growth factor I Stimulates glucose transport in osteo-
blasts and is eﬀective at much lower
concentrations than insulin
Alveolar bone regeneration 41, 76, 103, 104,
115 and 116
VEGF Vascular endothelial
growth factor
Induces endothelial cell proliferation,
promotes cell migration, inhibits
apoptosis and induces permeabilization
of blood vessels
Recruitment of progenitor cells
to the periodontal wound;
revascularization
41, 42, 46, 76
and 116
TSP-1 Thrombospondin-1 Major activator of TGF-b1, may play
a role in dentinogenesis and/or
maintenance of dentin and dental pulp
Cementum regeneration 76, 116 and 119
bFGF Basic-fibroblast growth factor Plays an essential role in the regulation
of cell proliferation, diﬀerentiation,
migration and apoptosis, and in the
regulation of embryonic development
Promotes the proliferation and
migration of periodontal
ligament fibroblasts
41, 42 and 104
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levels (Fig. 4). This product can be allowed to clot spontaneously,
together with the remaining blood components, in order to
produce a platelet rich fibrin (PRF) clot (Fig. 4C);56 alternatively,
it can be collected and submitted to further centrifugation steps
to produce platelet concentrates (PC) (Fig. 4D).57 The PC or the
PRP can be used directly or activated using several methods,
including the addition of thrombin,58 thromboplastin,59 calcium
salts58–61 or collagen62 (Fig. 4E). The platelet lysate (PL) can be
obtained after processing PRP or PC by freeze/thaw cycles41,42 of by
ultrasounds63 in order to disrupt the platelets’ membranes (Fig. 4F).
Table 3 Platelet-rich hemoderivatives-based tissue engineering strategies. Abbreviations: PRHds (platelet-rich hemoderivatives); PRP (platelet-rich
plasma); PG (platelet gel); PRGF (plasma rich in growth factors); PL (platelet lysate); GFs (growth factors); HA (hyaluronic acid); HAp (hydroxyapatite);
DFDBA (demineralized freeze-dried bone allograft); b-TCP (b-tricalcium phosphate); FDBA (freeze-dried bone allograft); BCP (biphasic calcium
phosphate), Ti (titanium implants)
Tissue engineering
approaches Biomaterials PRHds Aims Ref.
Fibrin hydrogels/
membranes
PRHds PRF, PG,a PLa – GFs delivery;
– Provisional matrix for progenitor cells delivery
66, 75, 85, 86,
89, 90 and 120
Encapsulation into hydrogels HA, silk, alginate,
gelatin
PRP, PRGF, PL – Release of GFs in a sustained manner;
– Extend the time of GFs release;
– Enhance encapsulated cells viability
50, 68, 81 and 82
Mixing with ceramics HAp, b-TCP, BCP PRP, PRF, PL – Modulate the osteogenic potential of
the PRHds;
– Improve the aggregation and cohesiveness
of particulate ceramics
79, 87, 121 and 122
Mixing with particulate
vital/demineralized/
decellularized bone
Particulate cancellous
bone, DFDBA, FDBA
PRF, PRP, PG – Improve the aggregation and cohesiveness
of particulate bone;
– Enhance the viability of live tissue;
– Promote bone regeneration
70, 78 and 88
Surface coating Ti PRP, PRGF, PL – Enrich grafts’ surface with fibrin and
growth factors;
– Enhance tissue integration
65 and 83
Membranes/sponges
of chemically
crosslinked PRHds
PL (+genipin) PL – Thrombin-free scaffolds;
– Delivery of GFs;
– Cell carriers
95
a After activation with thrombin.
Fig. 4 Platelet-rich hemoderivatives (PRHds). (A) The centrifugation of whole blood (B) induces the separation of the blood components into 3 layers.
(C) The upper layer, a yellowish solution composed mainly of plasma and platelets, coagulate spontaneously if no anticlotting agent was previously added
to the whole blood, originating a fibrin mesh rich in platelets and leucocytes termed platelet rich plasma (PRF). (D) The platelet concentrate (PC) also
called platelet-rich plasma (PRP) can be obtained from the upper layer of centrifuged whole blood supplemented with anticlotting agents or
by plasmapheresis. (E) The PC or PRP can suﬀer clotting induction, originating the platelet gel (PG), and plasma rich in growth factors (PRGF).
(F) Alternatively, the platelets of PC or PRP can be disrupted by freeze/thaw cycles or by ultrasounds, originating a solution of platelet lysate (PL).
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Other PRHDs subtypes can be defined based on the leukocyte
content (more information can be found elsewhere).64
Platelet-rich plasma (PRP)
PRP was defined by Marx57 as a volume of autologous plasma
that has a platelet concentration above blood baseline (between
1.5  105 ml1 and 3.5  105 ml1). Since the concentration of
platelets that has been proven to have therapeutic eﬃcacy for
bone healing is around 1  106 ml1,57,65 this has been estab-
lished as the platelet content that defines a platelet suspension as
PRP.57 Any platelet suspension in plasma with a concentration
above baseline can be termed platelet concentrate (PC). However,
in literature, some works using ‘‘PRP’’ either overlock the platelet
concentration66 or use PC at diﬀerent other.67 PRP can be used
directly or activated with thrombin and/or Ca2+ promoting the
formation of a fibrin network containing activated platelets,
termed platelet gel (PG), as depicted in Fig. 4E.68 The super-
natant, a solution of GFs, released upon platelets activation, in
blood plasma is called plasma rich in growth factors (PRGF).43,49
PRP has been proposed for TE applications as a source of
autologous growth factors (GFs).57 Moreover, its fibrin meshes
are adequate vehicles for mesenchymal stem cells (MSCs)
transplantation.69 Therefore, PRP and its derivatives have been
studied for the regeneration of several tissues including bone,57,70
cartilage71 and tendon.72 Additionally, PRP was shown to be an
alternative to the xenogenic fetal bovine serum as culture media
supplementation for the expansion of ASCs,73 and MSCs.74
Whitman et al.,70 in 1997, were the first to promote the use
of PRP, as PG, in oral surgical procedures. It was shown to
improve the aggregation and cohesiveness of particulate bone,
enhancing the osteogenesis in palatal bone defects.70
Regarding the repair of periodontal tissue, the application
of PRP along with the conventional periodontal therapies has
produced comparable or improved outcomes. For instance, PRP
administration after open flap debridement (OFD) produced higher
clinical attachment level (CAL) than OFD alone in the treatment of
mandibular degree II furcation defects in subjects suﬀering of
chronical periodontitis.66 Moreover, PRP alone or associated with a
collagen GTR membrane enhanced the attachment and reduced
the periodontal pocket deep in apicomarginal defects treated in
clinic.75 PRGF exerts positive eﬀects on periodontal ligament
fibroblasts (PDLFs), namely promoting their proliferation and
migration,76 which could justify the positive eﬀect of PRP on
re-gain of teeth attachment after periodontal disease.
It is more or less established that PRP has a positive eﬀect
in the treatment of periodontal soft tissues.77 Nevertheless,
PRP seems to be more eﬀective when combined with other
materials.77 Actually, PRP might enhance the osteogenic prop-
erties of the bone grafts and maintains the cohesiveness of
the materials.70 The combination of PRP with demineralized
freeze-dried bone allograft (DFDBA) produced significantly
greater clinical improvement in infrabony periodontal defects
than DFDBA with saline.78 Similar results were reported for
sinus floor augmentation, using PRP along with b-tricalcium
phosphate (b-TCP).79 Nevertheless, the eﬀect of PRP on bone
augmentation is still inconclusive.77,80
Some works have investigated the possibility to modulate the
release of PRP growth factors, as the eﬀect of PRP alone seems to
disappear a few days after administration.77 The incorporation
of PRP into hydrogels seems to be an adequate alternative.68,81,82
Fernandes and co-workers81 showed that the encapsulation of
PRP into alginate microbeads promoted the sustained release of
PDGF. Moreover, this system promoted faster obliteration of the
sagittal and coronal cranial sutures of mice embryonic calvaria.81
Finally, the coating of dental metallic implants with PRP proteins
improves their tissue integration. For instance, the osteointegration
of Ti implants was enhanced by coating the implant surface
with PRGF prior to insertion into the alveolus.83
Platelet-rich fibrin (PRF)
PRF consists of an autologous leukocyte-platelet-rich fibrin
matrix.84 It is a second generation PRHd proposed by
Choukroun56 as an easier to prepare and completely autologous
alternative to PRP (Fig. 4C).
For periodontal TE applications, adjunctive use of PRF with
OFD significantly improves the treatment of two and three wall
infrabony defects fill when compared to OFD alone 9 months
post operatively.85,86 The CAL obtained for degree II furcation
defects 9 months after the combined treatment of PRF and OFD
or PRP and OFD is comparable.66 In fact, the results reported
for PRF in periodontal treatment are very similar to those
reported for PRP.86
PRF was also shown to have a positive clinical impact in
the treatment of infrabony defects when combined with an
alloplast graft composed of b-tricalcium phosphate (b-TCP) and
hydroxyapatite (HAp) (OssiFit).87 Moreover, the combination
of PRF freeze-dried bone allograft (FDBA) reduced the healing
time in sinus floor elevation.88
The use of PRF membranes as cell-delivery vehicles for period-
ontal TE was also proposed. Wang and co-workers89 proposed a
multiphasic system composed of human PDL stem cells (PDLSCs)
and jaw bone mesenchymal stem cells (JBMSCs) cell sheets
placed on both the sides of a PRF membrane. This system tested
in vitro in simulated periodontal space comprising human
treated dentin matrix (TDM) and hydroxyapatite (HA)/tricalcium
phosphate (TCP) frameworks originated PDL- and bone-like
tissue, after eight weeks in culture.
Platelet lysate (PL)
PL is obtained by disruption of the platelets contained in
PC batches, either produced by centrifugation cycles42 or by
apheresis.41,42,90 It is a solution which contains most of the
growth factors common to PRHds.41,42 Therefore, the human
PL (hPL) has been proposed as prevailing alternative to fetal
bovine serum (FBS) supplement for several human cell
culture.41,91 Long term culture of human bone marrow stem
cells (hMSC) in medium supplemented with hPL maintained
the multipotency of hMSC, while protecting against the clonal
chromosomal instability detected in the FBS milieu.41 Similar
results were reported by Trubiani and co-workers92 for the
expansion of hPDLSCs.
Journal of Materials Chemistry B Review
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PL oﬀer several advantages over PRP and PRF for therapeutic
applications (Table 4): (1) the clot and platelet debris are
removed during PL processing, therefore, the PL is a solution
that hardly forms spontaneously a gel or retracts; (2) the freeze/
thaw cycles are easy to standardize and do not require the
addiction of any clot activator to release the platelet factors;
(4) the concentration of the growth factors and cytokines is
highly reproducible between batches, which can contribute for
more predictable outcomes; (3) it can be frozen and stored to be
readily available for further use.41
For TE applications, PL can be processed into a gel using
thrombin63 or loaded into carries for the sustained release
PL-origin factors.50,93,94 These constructs incorporating PL shown
potential to induce neovascularization,63 osteogenesis93,94 and
enhance periodontal re-attachment.17
Santo et al.93 incorporated PL into chondroitin sulfate/
chitosan nanocarriers, which were able to replace FBS supplemen-
tation in human adipose derived stem cells (hASCs) cultures with-
out compromising cell proliferation. Moreover, the release of PL
from nanocarriers was shown to enhance osteogenic commitment
of hASCs.93 PL can be also incorporated into photocrosslinkable
hydrogels produced by dissolution of a methacrylated glycos-
aminoglycan (e.g., hyaluronic acid50) into PL and using an adequate
photoinitiator. The produced hydrogels are able to release growth
factors with therapeutic interest in a controlled manner, support
the adhesion and proliferation of hPDLFs, displaying bacteriostatic
properties against Staphylococcus aureus.50 In a previous study
we described the production of PL-based membranes by self-
crosslinking of PL proteins with the natural origin crosslinker
genipin.95 This membranes were proved to be stable and non-
retractable for up to 28 days in PBS solution, and released basic
fibroblast growth factor (bFGF), a potent mitogen for PDLCs,92 in a
sustained manner.95 Furthermore, the PL-based membranes were
shown to provide adequate substrates for hASCs adhesion an
proliferation,95 thus suggesting the potential of PL to be used as
raw material for TE therapies. In order to evaluate the potential of
the PL-based membranes to regenerate the PDL, a bi-layered
system composed of the membrane and an injectable CaP incor-
porating PL-loaded PLGA microspheres was tested in a rat infrab-
ony 3-wall periodontal defect.17 The delivery of PDLCs with the
membranes did not produce therapeutic benefits, however, the
stabilization of the PL-based construct over the tooth root signifi-
cantly promoted the re-growth of periodontal tissue.17
Challenges for PRHds-based periodontal tissue engineering
In fact, the application of PRP or PRF has been proved to be a
real asset for periodontal TE, with improved86 or comparable96,97
clinical outcome in terms of gain of periodontal support
with conventional periodontal therapies such as open flap
debridement66,86 or GTR occlusive barriers.96 Still, the outcomes of
the PRP (and PRF) are fairly variable,97 and, despite the promising
eﬀectiveness of these hemoderivatives for periodontal regeneration
reported by some authors, others reported no beneficial98,99 or
even an inhibitory eﬀect100 for bone augmentation.
The causes of the variability can be related with the severity
of the defects, the choice of the grafting materials or patient
predisposition to periodontal disease.97 However, the hetero-
geneity of the techniques employed for the preparation of
PRHds, namely the diﬀerent platelet concentrations used,65,101
and the activation protocol might also interfere with the predict-
ability of the treatment outcomes. Commercially available kits
(e.g. PRGFs-Endorets, PCCSs, Harvests SmartPreps) have aimed
at establishing good manufacturing practice (GMP)-adherent
protocols for PRP derivatives production, reducing the protocol-
related variability. Nevertheless, diﬀerent PRP preparation kits
still yield significantly diﬀerent platelets concentration.67,101 In
a study, PCCSs PRP preparation yielded 1641800  426 820
platelets per ml, and the PRGFs-Endorets kit PRP preparation
513 630  139470 platelets per ml, with a proportional diﬀerence
in GFs content.67 Additionally, since the PRP and PRF have been
touted as autologous approaches, the donor-to-donor variability
can be an imponderable factor too.43,102,103
PRP104 and PL41 pools of diﬀerent donors yield more con-
sistent cytokine contents and single-donor batches. Moreover,
human PL pools produced using good manufacturing practices
(GMPs)-adherent protocols showed viral and bacterial sterility.41
Regarding the use of PL as an adjuvant for periodontal TE,
the studies are still very incipient. Given the above endorsed
arguments for the use of PL in therapeutic applications, and its
versatility, novel PL-based periodontal TE systems are expected.
Regarding the eﬀect of the PRHds’ GFs in tissue regenera-
tion, it is very unlikely that a protein cocktail which is able to
maintain the diﬀerentiation potential of stem cells isolated
from several diﬀerent tissues,41,42,76,105,106 would be able to
promote by its own the cell diﬀerentiation. In fact, the cyto-
kines present in the PRHds correlate mainly to wound healing
processes.41,43 Nevertheless, the periodontal healing outcomes
(Table 1) are not concomitant with the fully regain of period-
ontal function, as demanded by periodontal TE. Future strate-
gies should procure to drive the specific GFs to the adequate
periodontal compartment. For instance, the bFGF is known to
have a pro-angiogenic eﬀect107 and to promote the proliferation
of PDLCs108 (see Table 2 and Fig. 5). Therefore, for TE strategies
envisioning the regain of periodontal attachment, its delivery is
Table 4 Comparison between the properties of platelet rich hemoderivatives, based on46,49,51,55
Platelet rich
hemoderivative
Clot
retraction Standardization
Batch-to-batch
variability
Introduction of
xenogenic material
Readily
available
Autologous
therapy
Platelet rich plasma Yes No High Yesa Nob Yes
Platelet rich fibrin Yes Yes High No Nob Yes
Platelet lysate No Yes Low No Yes Yesc
a When activated with xenogenic thrombin. b Needs blood collection from patient. c Usually proposed as an allogenic approach.
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expected to be more eﬀective in the PDL compartment.36
However, for hard tissue regeneration, namely alveolar bone
and cementum, the morphogenic factors BMPs, TGF-b, TSP1
and IGF, are needed. These GFs exist among PRHds cytokines,
however, the anti-morphogenic PDGFs100 too, which could
justify the impaired osteogenic potential of PRHds.100,109 The
use of osteogenic materials together with PRHds has a syner-
gistic eﬀect. Nevertheless, the choice of an adequate material
might modulate the cytokines presented to the cells. Most of
the GFs have basic pI (TGF-b at pH 8.90; PDGF-A at pH 9.52;
PDGF-B at pH 9.39; VEGF-1 at pH 8.66; FGF-2 at pH 9.6), being
positively charged at physiologic pH. The strategies followed
to control GFs release involve the encapsulation of PRHds
into hydrogels of negatively charged polymers.50,68,81 In fact,
it seems that is possible to modulate the release of specific
PL-origin growth factors using materials with diﬀerent sulfa-
tion degrees.110 For instance, low sulfated polysaccharides
presented high aﬃnity to PDGF, while heparin showed high
aﬃnity only for VEGF, resulting in phenotypic changes in ASCs
seeded on surfaces coated with each polymer and PL.110
Finally, the TE strategies proposed so far for PRHds-based
periodontal TE are very simplistic and only few of them propose
dedicated approaches for each periodontal compartment. Future
strategies should procure to produce compartmentalized
approaches based on PRHds, employing specific materials,
architectures and cells for each tissue. Three dimensional-
printing technologies have been evolving in terms of precision
and versatility of printing.24,111 Moreover, the use of mild
bioprinting conditions would allow to print proteins,112 and
cell-laden scaﬀolds.113 Thus, the future of periodontal TE could
anticipate fully autologous and patient designed therapies for
the predictable regeneration of periodontal defects.
In sum, future research on PRHds’ application for periodontal
TE should focus on the following aspects:
– Definition of GMPs or standard procedures in order to
assure the reproducibility of the treatments;
– Investigate new materials to modulate the release of PRHd-
origin growth factors;
– Explore bioprinting technologies and develop printable PRHd-
carriers with defined architecture and chemical composition;
– Given the limited availability of some PRHds, study new
storage strategies or the safeness of allogenic administration.
Conclusions
The ultimate goal of TE directed for periodontal tissue is the full
regeneration of the lost tissues after trauma or periodontal
disease to their original morphology and function. Nevertheless,
the regeneration of periodontal tissue is a challenging task.
Current scientific evidences suggest that a single approach is
unlikely to succeed and the regeneration of periodontal tissue
depends upon the provision of a stable surface for the ingrowth
of both soft and hard tissues. In parallel, the invasion of period-
ontal wound with gingival soft tissue should be prevented. Of
paramount importance is the delivery of adequate signaling
molecules to promote the recruitment of suitable progenitor
cells and diﬀerentiate them into functional tissues. Therefore,
bi-layered compartmentalized systems provide the most promis-
ing design to meet the requirements of the various tissues
involved while addressing the need for preventing the invasion
of periodontal wound with gingival soft tissue.
The PRHds have arisen as an important source of GFs and
structural proteins for TE. They oﬀer the possibility of avoiding
the use of xenogenic materials providing a ‘‘natural’’ release
system for various GF involved in periodontal regeneration. The
ability to be incorporated into several TE scaﬀolds, improving
their biological performance enlarges the applicability of PRHds
for periodontal therapies. Nevertheless, the plurality of processing
protocols and the donor-to-donor variability still overshadow the
needed reproducibility of PRHds medical application.
Future works should focus on the definition of the most
adequate physicochemical design of scaﬀolds/materials aiming
the delivery of PRHds targeting specific periodontal tissues,
based, for instance, in sulfated polymers, known tomodulate the
release of specific PL growth factors.110 Additionally, attention
Fig. 5 Role of platelets in periodontal healing. The chemotactic growth factors
released from activated platelets (PDGF, TGF-b, bFGF) recruit progenitor cells
from the preserved periodontal tissue, namely periodontal ligament fibroblasts
(PDLFs) and mesenchymal stem cells from alveolar bone marrow (bmMSCs).
The fibrin clot provides a provisional matrix for cell colonization of the defect
area and the mitogenic eﬀect of some growth factors (PDGF, bFGF) promote
cell proliferation. The release of angiogenic factors (VEGF) will enhance the
formation of new vascular tissue and accelerate the healing process. Finally, the
morfogenic factors (TGF-b, BMPs, IGF, TSP-1) promote the progenitor cells
diﬀerentiation into new periodontal tissue.
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should be paid to reproducibility of the PRHds’ batches.
Finally, the preparation of PRHds is time consuming and
requires specific equipment which are not common in clinical
practice, therefore attention should be given to strategies for
preserving autologous PRHds and its storage. Alternatively, the
definition of GMPs aiming safeness of allogenic PRHds admin-
istration should be attempted.
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